Suche klinische Studie
Weitere Suchoptionen
216 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
DEUTSCHLAND
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
TUM Fakultät für Medizin
DEUTSCHLAND
Bayern
MÜNCHEN
SynCoRAS: Verbesserung der synaptischen Plastizität und der kognitiven Funktion bei Störungen des RAS-Signalweges (GeNeRARe-Studie)
kbo-Kinderzentrum München gemeinnützige GmbH
kbo-Kinderzentrum München
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Sicherheit von Abatacept bei der Behandlung von interstitiellen Lungenerkrankungen (ILD) bei Patienten mit variablem Immundefekt (CVID) und ähnlichen Erkrankungen.
Institution: Information not provided - DE
NIEDERLANDE
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIEDERLANDE
Zuid-Holland
ROTTERDAM
NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum
Afdeling Neurowetenschappen
SCHWEDEN
Region Skåne
LUND
plexifpc - Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief - SE
Skåne University Hospital, Lund
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult and pediatric participants with neurofibromatosis type 1 - ES
Institution: Information not provided - ES
VEREINIGTES KONIGREICH
Greater London
LONDON
A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
BELGIEN
ANTWERPEN
EDEGEM (ANTWERPEN)
WIDEA: Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
University Hospital Antwerp - UZA
Antwerp University Hospital
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
CREATE (EORTC-90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumor induced by causal alterations of ALK and/or MET - BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ADMIRAL: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation- BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia - BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
RISE/MRX-801: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de gastro-entérologie et hépatologie pédiatrique
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy - BE
Cliniques universitaires Saint-Luc - UCLouvain
Department of Hematology
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EXIST-LT: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301- BE
Universitair Ziekenhuis Brussel
Pediatric neurology / Neurologie Kinderen
BELGIEN
LIEGE
LIEGE
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 (phase II)- BE
CHU de Liège - Site du Sart Tilman
Department of Hematology / Hématologie clinique - CHU de Liège
BELGIEN
VLAAMS BRABANT
LEUVEN
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - BE
UZ Leuven - Campus Gasthuisberg
Laboratory of Pediatric Immunology
BELGIEN
VLAAMS BRABANT
LEUVEN
CRAD001M2X02B: An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304 - BE
UZ Leuven - Campus Gasthuisberg
Kinderen neurologie / Paediatric Neurology
DEUTSCHLAND
Baden-Württemberg
FREIBURG
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
CCI am Universitätsklinikum Freiburg
Centrum für Chronische Immundefizienz
DEUTSCHLAND
Baden-Württemberg
FREIBURG
TRANSATRA: Eine Phase I/II-Studie zu Dosisfindung und Wirksamkeit von Tranylcypromine bei Patienten mit nicht-APL AML
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
DEUTSCHLAND
Baden-Württemberg
FREIBURG
CA209-9P9: Phase 1/2 Studie zur Wirksamkeit von Nivolumab beim Rezidiv der akuten myeloischen Leukämie nach allogener hämatopoetischer Stammzelltransplantation
Universitätsklinikum Freiburg
Klinik für Innere Medizin I - Hämatologie, Onkologie und Stammzelltransplantation
DEUTSCHLAND
Baden-Württemberg
FREIBURG
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Freiburg
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Effectiveness and safety of mTOR-inhibitor in patients with tuberous sclerosis complex-KD
Universitätsklinikum Heidelberg
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
BLAST: Eine doppelblinde, Placebo-kontrollierte, randomisierte, multizentrische Phase II-Studie zur Untersuchung der Wirksamkeit von BL-8040 in Kombination mit einer Konsolidierungstherapie bei Patienten mit AML
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Baden-Württemberg
ULM
DEUTSCHLAND
Baden-Württemberg
ULM
Phase-1b-Studie mit Venetoclax und Alvocidib bei Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie
Universitätsklinikum Ulm
DEUTSCHLAND
Baden-Württemberg
ULM
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Ulm
DEUTSCHLAND
Baden-Württemberg
ULM
QUAZAR AML maintenance: Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit von oralem Azacitidin plus bestmögliche Unterstützende Behandlung versus bestmögliche unterstützende Behandlung als Erhaltungstherapie bei Patienten mit akuter myeloischer Leukämie mit vollständiger Remission
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
DEUTSCHLAND
Baden-Württemberg
ULM
SOPRA: Eine randomisierte, offene Phase 2-Studie des selektiven Inhibitors des nukleären Exports (SINE) Selinexor (KPT-330) gegenüber einer angegebenen Auswahl des Arztes bei Patienten ab 60 Jahren mit akuter myeloischer Leukämie, die für intensive Chemotherapie und/oder Transplantation nicht geeignet sind
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
DEUTSCHLAND
Baden-Württemberg
ULM
Eine multizentrische , offene, randomisierte Phase 3-Studie mit SGI-110 versus Behandlung nach Wahl bei unbehandelten Erwachsenen mit akuter myeloischer Leukämie, die keine Kandidaten für die intensive Remissionsinduktion Chemotherapie sind
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
DEUTSCHLAND
Baden-Württemberg
ULM
Die IDHENTIFY-STUDIE: Eine multizentrische, offene, randomisierte Phase III-Studie zum Vergleich der Wirksamkeit und Sicherheit von AG-221 (CC-90007) bei älteren Patienten mit fortgeschrittener AML und IDH2-Mutation
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
DEUTSCHLAND
Baden-Württemberg
ULM
AMLSG 30-18: Randomisierte Phase III Studie zur intensiven Standardchemotherapie versus intensiver Chemotherapie mit CPX-351 bei erwachsenen Patienten mit einer neu diagnostizierten akuten myeloischen Leukämie und intermediärem bzw. ungünstigem genetischen Risiko
Universitätsklinikum Ulm am Oberen Eselsberg
Klinik für Innere Medizin III
DEUTSCHLAND
Bayern
ERLANGEN
Eine Phase III, doppelt-verblindete, Placebo-kontrollierte, multizentrische, randomisierte Studie von Pracinostat in Kombination mit Azacitidin bei Patienten >= 18 Jahre mit neu diagnostizierter akuter myeloischer Leukämie, die für die Standardinduktionschemotherapie ungeeignet ist
Universitätsmedizin Erlangen
Universitätsklinikum Erlangen
DEUTSCHLAND
Bayern
MÜNCHEN
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
LMU Klinikum der Universität München - Campus Großhadern
LMU Klinikum
DEUTSCHLAND
Bayern
MÜNCHEN
AARON: Eine offene Phase-II-Studie von Relatlimab (BMS-986016) mit Nivolumab (BMS-936558) in Kombination mit 5-Azacytidin zur Behandlung von Patienten mit refraktärer/rückfälliger akuter myeloischer Leukämie und neu diagnostizierten älteren Patienten mit akuter myeloischer Leukämie
LMU Klinikum der Universität München - Campus Großhadern
Medizinische Klinik und Poliklinik III
DEUTSCHLAND
Bayern
MÜNCHEN
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
Medizinische Klinik und Poliklinik IV - Standort Ziemssenstraße
Medizinische Klinik und Poliklinik IV
DEUTSCHLAND
Bayern
REGENSBURG
AMLSG 26-16 / AML-ViVA: Randomisierte Phase II Studie mit Sicherheits-Run-In Phase zur Evaluation von niedrig-dosiertem Azacitidin, All-trans Retinsäure und Pioglitazon im Vergleich zu standard-dosiertem Azacitidin in Patienten >=60 Jahre mit akuter myeloischer Leukämie (AML), die refraktär sind auf Standardinduktionschemotherapie
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
DEUTSCHLAND
Bayern
REGENSBURG
CD-TCR-001: Eine offene, nicht randomisierte, multizentrische Dosis-Eskalations Phase-I/II-Studie mit Kontrollgruppe zur Bewertung der Sicherheit, Machbarkeit und vorläufigen Wirksamkeit von PRAME TCR-modifizierten T-Zellen, MDG1011, in Patienten mit Hochrisiko myeloischen und lymphoiden Neoplasien
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin III
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Offene, langfristige Extensionsbehandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der IEDAT-02-2015-Studie teilgenommen haben -DE-
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Sicherheitsstudie von AG-120 oder AG-221 in Kombination mit Induktions- und Konsolidierungstherapie bei Patienten mit neu diagnostizierter akuter myeloischer Leukämie mit IDH1- und/oder IDH2-Mutation
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
SAKK 30/13: Randomisierte Studie mit einer un-in-Dosis-Auswahlphase zur Beurteilung des Mehrwerts von Lenalidomid in Kombination mit einer Standard-Remissionsinduktionschemotherapie und einer Post-Emissionsbehandlung bei Patienten im Alter von 18-65 Jahren mit zuvor unbehandelter akuter myeloischer Leukämie (AML) oder hochriskanter Myelodysplasie (MDS) (IPSS-R-R-Risikowert > 4,5)
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine multizentrische, offene, 3-armige, 2-stufige, randomisierte Phase-2/3-Studie von ASP2215 (Gilteritinib), Kombination von ASP2215 Plus Azacitidin und Azacitidin allein in der Behandlung der neu diagnostizierten akuten myeloischen Leukämie mit FLT3-Mutation bei Patienten, die nicht für eine intensive Induktionschemotherapie in Frage kommen
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
BERLIN
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Charité - Universitätsmedizin Berlin
DEUTSCHLAND
Hamburg
HAMBURG
Phase-1b-Studie mit Venetoclax und Alvocidib bei Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie
UKE - Universitätsklinikum Hamburg-Eppendorf
DEUTSCHLAND
Hamburg
HAMBURG
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
UKE - Universitätsklinikum Hamburg-Eppendorf
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
OLE-IEDAT: Offene, langfristige, verlängerte Behandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der Studie IEDAT-02-2015 teilgenommen haben
Universitätsklinikum Frankfurt
Schwerpunkt Allergologie, Pneumologie und Mukoviszidose
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Frankfurt
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Eine randomisierte Phase II/III-Studie zu DACOGEN® (Decitabine) allein oder mit JNJ-56022473 (Anti CD123) bei AML-Patienten, für die keine intensive Chemotherapie möglich ist
Universitätsklinikum Frankfurt
Universitäres Centrum für Tumorerkrankungen (UCT) Frankfurt
DEUTSCHLAND
Niedersachsen
BRAUNSCHWEIG
Eine multizentrische, doppelblinde, randomisierte, Placebo-kontrollierte Phase III-Studie zum Vergleich von Idasanutlin (Antagonist von MDM2) plus Cytarabin versus Cytarabin plus Placebo bei Patienten mit rezidivierender oder refraktärer akuten myeloischen Leukämie
Städtisches Klinikum Braunschweig - Standort Celler Straße
Klinik für Hämatologie und Onkologie
DEUTSCHLAND
Niedersachsen
HANNOVER
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Medizinische Hochschule Hannover
Medizinische Hochschule Hannover (MHH)
DEUTSCHLAND
Nordrhein-Westfalen
BONN
Eine internationale, multizentrische, offene Studie zur Bewertung der Wirksamkeit und Sicherheit von zwei verschiedenen Impfregimen der Immuntherapie mit allogenen dendritischen Zellen, DCP-001, bei Patienten mit akuter myeloischer Leukämie, die mit anhaltender MRD in Remission sind
Universitätsklinikum Bonn (AöR)
Universitätsklinikum Bonn
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
AML-BFM 2012: Klinische Prüfung zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen
Universitätsklinikum Essen
Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Klinische Phase-III-Studie zum Vergleich von Treosulfan-basierter Konditionierung mit Busulfan-basierter dosisreduzierter Konditionierung (RIC) vor allogener hämatopoetischer Stammzelltransplantation bei Patienten mit Akuter Myeloischer Leukämie (AML) oder Myelodysplastischem Syndrom (MDS), die für eine Standard-Konditionierungsbehandlung nicht geeignet sind
Universitätsklinikum Essen
Klinik für Knochenmarktransplantation
DEUTSCHLAND
Nordrhein-Westfalen
MÜNSTER
PAZOPANIB-AML: Phase II-Pilot-Studie mit Pazopanib bei Patienten mit rezidivierender oder refraktärer akuter myeloischer Leukämie oder bei der Erstdiagnose wenn keine intensive Behandlung möglich ist
Universitätsklinikum Münster
Medizinische Klinik und Poliklinik A
DEUTSCHLAND
Rheinland-Pfalz
MAINZ
DEUTSCHLAND
Sachsen
DRESDEN
DaunoDouble: Randomisierter Vergleich zwischen zwei Dosierungen von Daunorubicin und zwischen Einfach- und Doppel-Induktionstherapie bei erwachsenen Patienten mit Akuter Myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
DEUTSCHLAND
Sachsen
DRESDEN
Eine multizentrische, offene Phase I-Dosiseskalationsstudie mit GEM333 bei rezidivierender oder refraktärer akuter myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I
DEUTSCHLAND
Sachsen
DRESDEN
ETAL3-ASAP: Phase III Studie zu Cytarabine und Mitoxantrone als Induktionstherapie vor SZT bei AML
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
DEUTSCHLAND
Sachsen
DRESDEN
HINKL: Eine randomisierte, kontrollierte Phase-2 Studie zum Wirksamkeitsnachweis der Immuntherapie mit haploidenten natürlichen Killerzellen bei Hochrisiko akuter myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Nationales Centrum für Tumorerkrankungen Dresden
DEUTSCHLAND
Sachsen
DRESDEN
Phase-1b-Studie mit Venetoclax und Alvocidib bei Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
DEUTSCHLAND
Sachsen
DRESDEN
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
DEUTSCHLAND
Sachsen
LEIPZIG
DELTA: Randomisierte Placebo-kontrollierte Phase-II-Studie zu Decitabin/Azacitidin in Kombination mit oder ohne Eltrombopag bei Patienten mit akuter myeloischer Leukämie = / > 65 Jahre, für die eine intensive Chemotherapie nicht in Frage kommt
Universitätsklinikum Leipzig AöR
Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
DEUTSCHLAND
Sachsen
LEIPZIG
Eine internationale, multizentrische, offene Studie zur Bewertung der Wirksamkeit und Sicherheit von zwei verschiedenen Impfregimen der Immuntherapie mit allogenen dendritischen Zellen, DCP-001, bei Patienten mit akuter myeloischer Leukämie, die mit anhaltender MRD in Remission sind
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
DEUTSCHLAND
Sachsen
LEIPZIG
Eine offene multizentrische Phase-1b-Studie mit JNJ-74494550 (Cusatuzumab; monoklonaler Antikörper gegen CD70) in Kombination mit einer Hintergrundtherapie zur Behandlung von Patienten mit akuter myeloischer Leukämie
Universitätsklinikum Leipzig AöR
UCCL - Universitäres Krebszentrum Leipzig
DEUTSCHLAND
Schleswig-Holstein
KIEL
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Innere Medizin I
ESTLAND
Tartu
TARTU
Phase III study to evaluate GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Haematology and Oncology Clinic - Tartu University Hospital
Department of Radio and Oncotherapy
FINNLAND
Finland
HELSINKI
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FI
HUS - Helsinki University Hospital
Comprehensive Cancer Center
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
EXIST-3: A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures (Phase III) - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - FR
Institution: Information not provided - FR
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Léon Bérard
Centre Léon Bérard
FRANKREICH
ILE-DE-FRANCE
PARIS
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Hôpital Saint Louis
FRANKREICH
ILE-DE-FRANCE
PARIS
A Phase 3 Open-label Randomized Study of Quizartinib AC220 Monotherapy Versus Salvage Chemotherapy in Subjects With Feline McDonough Sarcoma FMS Like Tyrosine Kinase 3 Internal Tandem Duplication FLT3 ITD Positive Acute Myeloid Leukemia AML Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation HSCT Consolidation - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service : Centre des Maladies du Sang
FRANKREICH
ILE-DE-FRANCE
PARIS
SAMBA-trial: Investigation of efficacy of the antibody JNJ-56022473 in MDS and AML patients, in which the treamtment with hypomethylating agents fails or the treatment with hypomethylating agents results in a relapse (Phase II) - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service d'Hématologie seniors
FRANKREICH
ILE-DE-FRANCE
PARIS
WAS FUP : Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08) - FR
Hôpital Necker-Enfants Malades
Département de Biothérapie - Unité d'Hémaphérèse Thérapeutique
FRANKREICH
ILE-DE-FRANCE
PARIS
FancoMob : Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy (Phase I-II)
Hôpital Necker-Enfants Malades
Service d'Hématologie adulte
FRANKREICH
OCCITANIE
TOULOUSE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
IUCT Oncopole - CLCC Institut Claudius Regaud
Bureau des études cliniques
FRANKREICH
PAYS DE LA LOIRE
ANGERS
BIG-1 : Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
CHU d'Angers
Service des Maladies du sang
FRANKREICH
PAYS DE LA LOIRE
NANTES
FRANKREICH
PAYS DE LA LOIRE
NANTES
Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANKREICH
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
IRLAND
County Dublin
DUBLIN
A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission - IE
Tallaght University Hospital
Department of Haematology
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Single Arm, Open-label Clinical Trial of Hematopoietic Stem Cell Gene Therapy With Cryopreserved Autologous CD34+ Cells Transduced With Lentiviral Vector Encoding WAS cDNA in Subjects With Wiskott-Aldrich Syndrome (WAS)
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission - IT
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
ADMIRAL: A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation - IT
Institution: Information not provided - IT
ITALIEN
LAZIO
ROMA
A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and/or Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
Ambulatorio Polispecialistico per le Malattie Rare
ITALIEN
LIGURIA
GENOVA
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602) - IT
Ospedali Galliera
S.S.D. Ematologia
ITALIEN
LOMBARDIA
MILANO
TIGET-WAS - A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome
Istituto San Raffaele Telethon per la Terapia Genica - TIGET
Istituto San Raffaele Telethon per la Terapia Genica
NIEDERLANDE
Groningen
GRONINGEN
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >=66 years - NL
UMCG - Universitair Medisch Centrum Groningen
Afdeling Hematologie
NIEDERLANDE
Noord-Holland
AMSTERDAM
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) in patients aged >= 66 years - NL
Amsterdam UMC, locatie VUmc
Afdeling Hematologie
NIEDERLANDE
Zuid-Holland
LEIDEN
NIEDERLANDE
Zuid-Holland
LEIDEN
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
LUMC - Leids Universitair Medisch Centrum
Afdeling Hematologie
NIEDERLANDE
Zuid-Holland
ROTTERDAM
RATE trial: Randomised open label cross-over study into the efficacy of rapamycin in children with Tuberous Sclerosis Complex with intractable epilepsy (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
NIEDERLANDE
Zuid-Holland
ROTTERDAM
RAPIT trial: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum
Afdeling Kinderneurologie
OSTERREICH
OBERÖSTERREICH
LINZ
AMLSG 16-10: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication - AT
Ordensklinikum Linz GmbH Barmherzige Schwestern
Interne I - Internistische Onkologie, Hämatologie u. Gastroenterologie
OSTERREICH
SALZBURG
SALZBURG
AMLSG 16-10: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Universitätsklinik für Innere Medizin III
OSTERREICH
TIROL
INNSBRUCK
AMLSG 16-10: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication - AT
Medizinische Universität Innsbruck
Universitätsklinik für Innere Medizin V - Hämatologie und Onkologie
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
POLO-AML-2: A phase III randomised, double-blind, controlled, parallel group study of intravenous Volasertib in combination with subcutaneous low-dose Cytarabine vs. placebo + low-dose Cytarabine in patients greater or equal to 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
MIRROS: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients >18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
BRIGHT AML1019: A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia (phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
TALAPRO-1: A phase 2, open-label, response rate study of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
HOVON 156 AML: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
HOVON 150 AML: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed AML or MDS With Excess Blasts-2, With an IDH1 or IDH2 Mutation [...] - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial (Phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A multi-center continuation study evaluating azacitidine with or without glasdegib (PF-04449913) in patients with previously untreated acute myeloid leukemia, myelodysplastic syndrome or chronic myelomonocytic leukemia (phase 3) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
QUAZAR AML-001: A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
AMLSG 16-10: Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication - AT
Hanusch Krankenhaus
3. Medizinische Abteilung (Hämatologie und Onkologie)
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.-GB
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - CH
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia - CH
Institution: Information not provided - CH
SPANIEN
Comunidad Valenciana
VALENCIA
QUAZAR AML-001: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPANIEN
Comunidad Valenciana
VALENCIA
IDHENTIFY: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPANIEN
Comunidad Valenciana
VALENCIA
QUIWI: A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-type AML - ES
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
FANCOLEN-1: Clinical Trial Phase I/II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with Fanconi Anemia Subtype A
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively [...] - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy -GB
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
QuANTUM-First: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
FANCOLEN-II: A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia Subtype A - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
LAMVYX: A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute myeloid leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
PEVOLAM: A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without Glasdegib (PF-04449913) or Azacitidine with or without Glasdegib in patients with previously untreated acute myeloid leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
HOVON 150 AML: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed AML or MDS With Excess Blasts-2, With an IDH1 or IDH2 Mutation [...] - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
LIBRETTO-531: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
HOVON 156 AML: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase I-II, Multicentre, Open Label Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine, Plus Venetoclax and Quizartinib in Newly Diagnosed Acute Myeloid Leukemia Patients Aged Equal or More Than 60 Years Old Ineligible for Standard Induction Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE-2: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician's Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) in patients with Fanconi Anaemia Subtype A - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
ENHANCE-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination With Azacitidine in Subjects With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
LAVA: A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD1d-positive chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
An open clinical trial, phase II to evaluate the efficacy and safety of the use of eltrombopag in children and adolescents with Fanconi Anemia - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Hematología y Hemoterapia
SPANIEN
Madrid
MADRID
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial - ES
Hospital Universitario Fundación Jiménez Díaz
Servicio de Hematología y Hemoterapia
SPANIEN
Madrid
MADRID
MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study - ES
Hospital Universitario La Paz
SPANIEN
Madrid
MADRID
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - ES
Hospital Universitario La Paz
Servicio de Neurología
SPANIEN
Madrid
MADRID
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study - ES
Hospital Universitario La Paz
Servicio de Neurología infantil
VEREINIGTE STAATEN
Ohio
CINCINNATI
Quercetin in Children With Fanconi Anemia; a Pilot Study (Phase 1/2) - US
Cincinnati Children's Hospital Medical Center
Department of Pediatry
VEREINIGTE STAATEN
Pennsylvania
PHILADELPHIA
Reinstituting Natural Killer Cell Cytotoxicity and Cytoskeletal Dynamics in Wiskott-Aldrich Syndrome With IL-2 Therapy (Phase 1) - US
The Children's Hospital of Philadelphia
Department of Allergy and Asthma
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma-GB
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Glasgow
GLASGOW
MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy - UK
Royal Hospital For Children, NHS Greater Glasgow & Clyde
Paediatrics (Ground Floor, Zone 1)
VEREINIGTES KONIGREICH
Greater London
LONDON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08) - GB
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
VEREINIGTES KONIGREICH
Greater London
LONDON
CREATE (EORTC 90101): Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET - UK
UCLH NHS Foundation Trust - University College Hospital
The London Sarcoma Service
VEREINIGTES KONIGREICH
Greater London
LONDON
MCRN007: An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome (phase II) - UK
University College London Hospitals, NHS Foundation Trust
Endocrinology Department
VEREINIGTES KONIGREICH
Greater Manchester
MANCHESTER
A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission - UK
The Christie, NHS Foundation Trust
The Christie NHS Foundation Trust
VEREINIGTES KONIGREICH
Nottinghamshire
NOTTINGHAM
AML18: A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome (Phase III) - UK
LAM Action Nottingham, Voluntary Action Centre
Department of Haematology
VEREINIGTES KONIGREICH
Oxfordshire
OXFORD
A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies
Churchill Hospital
Department of Haematology
VEREINIGTES KONIGREICH
South Glamorgan
CARDIFF
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia-GB
University Hospital of Wales
Department of Haematology
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
Hospices Civils de Lyon
FRANKREICH
ILE-DE-FRANCE
BOBIGNY
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
CHU Paris Seine-Saint-Denis - Hôpital Avicenne
FRANKREICH
ILE-DE-FRANCE
PARIS
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
AP-HP.Sorbonne Université - Hôpital Saint-Antoine
CHU Paris Est - Hôpital Saint-Antoine
ITALIEN
LAZIO
ROMA
The NUVOLA TRIAL: Neoadjuvant Chemotherapy in Unresectable oVarian Cancer With OLAparib and Weekly Carboplatin Plus Paclitaxel: A Phase II Open-label Multicentre Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Ginecologia Oncologica
NIEDERLANDE
Gelderland
NIJMEGEN
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI
Radboudumc - Radboud universitair medisch centrum
Afdeling Tumor Immunologie
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP) - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Timely: Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. A Randomized, Parallel, Multicenter, Controlled Trial - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects With Familial Adenomatous Polyposis - ES
Institution: Information not provided - ES
SPANIEN
Navarra
PAMPLONA
CaPP3 Spain: A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme - ES
Complejo Hospitalario de Navarra
Servicio de Genética
Multinationale klinische Studie(n)
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different Vismodegib regimens in patients with multiple Basal Cell Carcinoma
Institution: Information not provided - CH
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
SAMBA-trial: Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy
Institution: Information not provided - DE
DEUTSCHLAND
Hessen
WIESBADEN
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
AbbVie Deutschland GmbH & Co. KG
FRANKREICH
ILE-DE-FRANCE
EVRY
WAS FUP : Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08)
Généthon
Centre de Recherche Généthon
FRANKREICH
ILE-DE-FRANCE
PARIS
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Institution: Information not provided - IT
NIEDERLANDE
Groningen
GRONINGEN
HO155: A Randomized Phase II Multicenter Study to Assess the Tolerability and Efficacy of the Addition of Midostaurin to 10-day Decitabine Treatment in Unfit Adult Acute Myeloid Leukemia and High Risk Myelodysplasia Patients
UMCG - Universitair Medisch Centrum Groningen
SCHWEIZ
Suisse Alémanique
BASEL
EXIST-2: Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Novartis International AG
SCHWEIZ
Suisse Alémanique
BASEL
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients =18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Institution: Information not provided - CH
SPANIEN
Madrid
MADRID
EUROFANCOLEN: Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action
CIEMAT - Centro de Investigaciones Energéticas Medioambientales y Tecnológicas
Terapias innovadoras en el sistema hematopoyético
VEREINIGTE STAATEN
California
FOSTER CITY
MERGE - MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Mirum Pharmaceuticals, Inc.
VEREINIGTE STAATEN
California
PLEASANTON
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc
VEREINIGTE STAATEN
California
PLEASANTON
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies (Phase II)
Astex Pharmaceuticals, Inc
VEREINIGTE STAATEN
New Jersey
EDISON
QuANTUM First: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Daiichi Sankyo Pharma Development
VEREINIGTE STAATEN
New Jersey
RARITAN
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Janssen Research & Development, LLC
Janssen Research & Development, LLC.
VEREINIGTE STAATEN
New York
NEW YORK
VEREINIGTE STAATEN
Texas
HOUSTON
CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
CASCADE: A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Institution: Information not provided - UK
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
Institution: Information not provided - DE
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US